552 related articles for article (PubMed ID: 28299658)
1. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
5. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
6. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
7. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
8. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
9. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein.
Day RB; Hickman JA; Xu Z; Katerndahl CD; Ferraro F; Ramakrishnan SM; Erdmann-Gilmore P; Sprung RW; Mi Y; Townsend RR; Miller CA; Ley TJ
J Clin Invest; 2023 Dec; 134(4):. PubMed ID: 38061017
[TBL] [Abstract][Full Text] [Related]
11. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
[TBL] [Abstract][Full Text] [Related]
12. Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia.
Flach J; Shumilov E; Joncourt R; Porret N; Tchinda J; Legros M; Scarpelli I; Hewer E; Novak U; Schoumans J; Bacher U; Pabst T
Genes Chromosomes Cancer; 2020 Apr; 59(4):268-274. PubMed ID: 31756777
[TBL] [Abstract][Full Text] [Related]
13. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
Abe A; Yamamoto Y; Katsumi A; Okamoto A; Tokuda M; Inaguma Y; Yamamoto K; Yanada M; Kanie T; Tomita A; Akatsuka Y; Okamoto M; Kameyama T; Mayeda A; Emi N
Int J Hematol; 2018 Aug; 108(2):208-212. PubMed ID: 29264741
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
[TBL] [Abstract][Full Text] [Related]
16. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
19. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
[TBL] [Abstract][Full Text] [Related]
20. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
